Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Yum! Brands, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Yum! Brands, Inc. trades at $164.28 (market cap $46.16B). The key difference: Yum! Brands, Inc. is far larger — about 10.3× ACADIA Pharmaceuticals Inc.'s market cap, and Yum! Brands, Inc. pays a 1.79% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | YUM | |
|---|---|---|
Market Cap | $4.49B | $46.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $168.16 |
52-Week Low | $20.06 | $138.21 |
Enterprise Value | $3.69B | $57.43B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
YUM trades at $167.49, up 1.68% today, near its consensus price target of $174.00. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentals are solid with revenue growth from $7.5B in 2024 to $8.2B in 2025 and a net income margin of 20.48%. Recent news highlights the $2.7 billion sale of Pizza Hut, aimed at streamlining operations and funding a $4 billion share repurchase, signaling strategic focus on KFC and Taco Bell.
The outlook for YUM is cautiously optimistic, supported by earnings beats and strategic divestiture, but high debt levels and competitive pressures pose risks. Analyst consensus leans hold with a 37.25% buy rating, suggesting moderate upside potential. Investors should weigh the benefits of capital returns against execution risks in a challenging consumer discretionary environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
